Lyell Immunopharma (LYEL) Non Operating Income (2021 - 2026)
Lyell Immunopharma (LYEL) posted Non Operating Income of $2.2 million for Q1 2026, down 18.01% sequentially from $2.7 million in Q4 2025, and down 57.58% YoY from $5.2 million in Q1 2025.
Lyell Immunopharma (LYEL) Non Operating Income (2021 - 2026) Analysis & Trends
Lyell Immunopharma has reported Non Operating Income for 6 years, with the latest figure at $2.2 million in Q1 2026.
- Quarterly Non Operating Income fell 57.58% year-over-year to $2.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $6.6 million (down 53.43% YoY) and the FY2025 annual result came in at $13.1 million, down 17.01% from the prior year.
- Non Operating Income fell to $2.2 million in Q1 2026 per LYEL's latest filing, from $2.7 million in the prior quarter.
- Over five years, Non Operating Income peaked at $6.6 million in Q3 2023 and troughed at -$5.1 million in Q1 2024.
- A 5-year average of $2.5 million and a median of $3.3 million in 2025 frame the typical range for Non Operating Income.
- The widest YoY moves for Non Operating Income: up 1351.59% in 2022, down 1434.62% in 2022.
- Over 5 years, Non Operating Income stood at $6.4 million in 2022, then rose by 2.99% to $6.6 million in 2023, then sank by 151.49% to -$3.4 million in 2024, then surged by 179.01% to $2.7 million in 2025, then fell by 18.01% to $2.2 million in 2026.
- According to Business Quant data, Non Operating Income over the past three periods registered $2.2 million, $2.7 million, and -$1.6 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Op. Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 234.30 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -139.24 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | - |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 12.40 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | -51.63 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -53.64 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | - |
| 10 | Lyell Immunopharma | 326.39 Mn | 326.39 Mn | - | 2.58 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 2.58 Mn |
| Mar 31, 2026 | 2.19 Mn |
| Dec 31, 2025 | 2.68 Mn |
| Sep 30, 2025 | -1.59 Mn |
| Jun 30, 2025 | 3.28 Mn |
| Mar 31, 2025 | 5.17 Mn |
| Dec 31, 2024 | -3.39 Mn |
| Sep 30, 2024 | 5.92 Mn |
| Jun 30, 2024 | 6.36 Mn |
| Mar 31, 2024 | -5.09 Mn |
| Dec 31, 2023 | 6.58 Mn |
| Sep 30, 2023 | 6.61 Mn |
| Jun 30, 2023 | 5.26 Mn |
| Mar 31, 2023 | 4.50 Mn |
| Dec 31, 2022 | 6.39 Mn |
| Sep 30, 2022 | -3.82 Mn |
| Jun 30, 2022 | 938,000.00 |
| Mar 31, 2022 | 397,000.00 |
| Dec 31, 2021 | 440,000.00 |
| Sep 30, 2021 | 286,000.00 |